Compare ResMed Inc. (RMD) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs ProShares UltraPro QQQ ETF — how do they compare? ResMed Inc. trades at $230.05 (market cap $31.89B), while ProShares UltraPro QQQ ETF trades at $81.26 (market cap $38.74B). The key difference: ProShares UltraPro QQQ ETF is the larger of the two by market cap, and ResMed Inc. pays a 1.16% dividend while ProShares UltraPro QQQ ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and ProShares UltraPro QQQ ETF for 24 Days on average.
| RMD | TQQQ | |
|---|---|---|
Market Cap | $31.89B | $38.74B |
Volume | 618,314 | 65,384,797 |
Sector | Health | Leveraged / Inverse |
52-Week High | $277.88 | $87.22 |
52-Week Low | $182.82 | $37.89 |
Typical Hold Time | 51 Days | 24 Days |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
TQQQ trades at $81.28, down 2.78% on the day, with technical indicators showing a bullish bias despite recent selling pressure. The ETF maintains a strong position near its pivot point of $81, supported by positive moving average signals. Recent news highlights ongoing institutional interest alongside concerns about hidden costs and volatility risks inherent in leveraged ETF structures.
The outlook remains cautiously optimistic given the bullish technical setup, though investors face significant volatility risks amplified by the 3x leverage structure. Key opportunities include exposure to Nasdaq-100 growth, while risks center on expense ratios, financing costs, and potential market corrections that could magnify losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
